Please login to the form below

Not currently logged in
Email:
Password:

Sosei

This page shows the latest Sosei news and features for those working in and with pharma, biotech and healthcare.

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Surprise findings from primate studies. Sosei and Allergan have been forced to call a halt to testing of a drug for Alzheimer’s disease and other forms of dementia after cancer ... We were very surprised to see these results given the safety profile

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Whereas in the past the sector had “a very singular focus on amyloid”, Sosei Heptares’ chief R&D officer Malcolm Weir said he now thinks it is looking at targets “in ... Other groups, including Sosei Heptares, are working on novel ways to modify

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    Dr Fiona Marshall has joined MSD from Heptares Therapeutics, the UK biotech company she co-founded more than a decade ago, which was acquired by Sosei in 2015.

  • Deal Watch March 2017 Deal Watch March 2017

    20. Heptares/ Sosei Group. Daiichi Sankyo. Licence. G protein coupled receptor for pain relief.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Not disclosed. Staying in oncology, AstraZeneca closed an exclusive global licence with Heptares [owned by Sosei] securing a headline value of $510m. ... Acquisition–asset. 570. Heptares [Sosei]. AZ. HTL 1071 immuno‐oncology small molecule and other

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc.

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Metrion Biosciences adds to its board Metrion Biosciences adds to its board

    Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.

  • Sosei appoints CFO Sosei appoints CFO

    Andrew Oakley joins the Tokyo-based pharma firm. Andrew Oakley has joined Tokyo-based pharmaceutical firm Sosei as chief financial officer, succeeding Hidetoshi Torami. ... Peter Bains, chief executive officer of Sosei, said: “Andrew brings a wealth of

  • Sosei appoints chief operating officer Sosei appoints chief operating officer

    Tokyo, Japan-based Sosei has appointed Peter Bains as its chief operating officer and representative executive officer. ... In this role, Bains will oversee all of the pharmaceutical firm's operational activities, reporting to Shinichi Tamura, Sosei's

  • Dr David Chiswell joins Kymab Dr David Chiswell joins Kymab

    He brings over 30 years of biotechnology expertise to the firm, having held senior management positions at a number of pharmaceutical companies, including Arakis, Arrow Therapeutics, Daniolabs and Sosei.

More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics